Here you'll find an up-to-date collection of CADTH’s oncology-related products.
The bundle includes reports and other resources on a variety of topics related to the diagnosis and treatment of cancer. CADTH has reviewed the evidence on various cancer treatments, screening and diagnostic technologies, and ways to manage symptoms associated with cancer and its treatment.
You can also visit the pan-Canadian Oncology Drug Review (pCODR) section of the CADTH website to access pCODR cancer drug funding recommendations. pCODR is an evidence-based, cancer drug review process designed to bring consistency and clarity to the assessment of cancer drugs. pCODR uses information gained through its reviews of clinical evidence, cost-effectiveness, and patient perspectives to make recommendations to Canada's provinces and territories (except Quebec) that they can use to guide their drug funding decision-making.
We’ve selected the following materials to get you started:
- Axicabtagene Ciloleucel for Adults With Relapsed or Refractory Large B-cell Lymphoma (Optimal Use Project, May 2019)
- In Brief: Tisagenlecleucel (Kymriah) for Pediatric Acute Lymphoblastic Leukemia and Diffuse Large B-Cell Lymphoma (Summary, January 2019)
- Magnetic Resonance Imaging-Guided Radiotherapy Delivery Systems for Cancer Treatment: A Review of Clinical Effectiveness, Cost-Effectiveness and Guidelines (Summary With Critical Appraisal, March 2019)
- HPV Testing for Primary Cervical Cancer Screening (Optimal Use Project, March 2019)